Genital Chlamydia trachomatis: Understanding the roles of innate and adaptive immunity in vaccine research

Clinical Microbiology Reviews

Volumn 27, Issue 2, 2014, Pages 346-370

  Vasilevsky, Sam ^a   Greub, Gilbert ^b   Nardelli Haefliger, Denise ^a   Baud, David ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL VACCINE; CHLAMYDIAL VACCINE; EPITOPE; GAMMA INTERFERON; PLASMID DNA; POLYMER; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL MODEL; ARTICLE; BIOLOGY; CHLAMYDIASIS; DENDRITIC CELL; ECTOPIC PREGNANCY; GUINEA PIG; HUMAN; IMMUNE RESPONSE; INFERTILITY; INNATE IMMUNITY; LAPAROSCOPY; MACACA NEMESTRINA; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PELVIC INFLAMMATORY DISEASE; POLYMERASE CHAIN REACTION; PREMATURE LABOR; T LYMPHOCYTE; VACCINATION; CHLAMYDIA TRACHOMATIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOGRANULOMA VENEREUM;

ADAPTIVE IMMUNITY; BACTERIAL VACCINES; CHLAMYDIA TRACHOMATIS; HUMANS; IMMUNITY, INNATE; LYMPHOGRANULOMA VENEREUM;

EID: 84897563584     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00105-13     Document Type: Article

References (237)

1. Bebear C, de Barbeyrac B. 2009. Genital Chlamydia trachomatis infections. Clin. Microbiol. Infect. 15:4-10. http://dx.doi.org/10.1111/j.1469-0691.2008.02647.x.
2. World Health Organization. 2008. Global incidence and prevalence of selected curable sexually transmitted infections. World Health Organization, Geneva, Switzerland.
3. Baud D, Goy G, Jaton K, Osterheld MC, Blumer S, Borel N, Vial Y, Hohlfeld P, Pospischil A, Greub G. 2011. Role of Chlamydia trachomatis in miscarriage. Emerg. Infect. Dis. 17:1630-1635. http://dx.doi.org /10.3201/eid1709.100865.
4. Karaer A, Mert I, Cavkaytar S, Batioglu S. 2013. Serological investigation of the role of selected sexually transmitted infections in the aetiology of ectopic pregnancy. Eur. J. Contracept. Reprod. Health Care 18:68-74. http://dx.doi.org/10.3109/13625187.2012.744818.
5. Kavanagh K, Wallace LA, Robertson C, Wilson P, Scoular A. 2013. Estimation of the risk of tubal factor infertility associated with genital chlamydial infection in women: a statistical modelling study. Int. J. Epidemiol. 42:493-503. http://dx.doi.org/10.1093/ije/dyt011.
6. Gaydos CA, Wright C, Wood BJ, Waterfield G, Hobson S, Quinn TC. 2008. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex. Transm. Dis. 35:233-237. http://dx.doi.org/10.1097/OLQ.0b013e31815c11fe.
7. Hosenfeld CB, Workowski KA, Berman S, Zaidi A, Dyson J, Mosure D, Bolan G, Bauer HM. 2009. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex. Transm. Dis. 36:478-489. http://dx.doi.org/10.1097/OLQ.0b013e3181a 2a933.
8. Mariotti SP, Pascolini D, Rose-Nussbaumer J. 2009. Trachoma: global magnitude of a preventable cause of blindness. Br. J. Ophthalmol. 93: 563-568. http://dx.doi.org/10.1136/bjo.2008.148494.
9. Senn L, Hammerschlag MR, Greub G. 2005. Therapeutic approaches to Chlamydia infections. Expert Opin. Pharmacother. 6:2281-2290. http: //dx.doi.org/10.1517/14656566.6.13.2281.
10. Burton MJ, Mabey DC. 2009. The global burden of trachoma: a review. PLoS Negl. Trop. Dis. 3:e460. http://dx.doi.org/10.1371/journal.pntd.0000460.
11. Hu VH, Holland MJ, Burton MJ. 2013. Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl. Trop. Dis. 7:e2020. http://dx.doi.org/10.1371/journal.pntd.0002020.
12. Peuchant O, Baldit C, Le Roy C, Trombert-Paolantoni S, Clerc M, Bebear C, de Barbeyrac B. 2011. First case of Chlamydia trachomatis L2b proctitis in a woman. Clin. Microbiol. Infect. 17:E21-E23. http://dx.doi.org/10.1111/j.1469-0691.2011.03661.x.
13. Verweij SP, Ouburg S, de Vries H, Morre SA, van Ginkel CJ, Bos H, Sebens FW. 2012. The first case record of a female patient with bubonic lymphogranuloma venereum (LGV), serovariant L2b. Sex. Transm. Infect. 88:346-347. http://dx.doi.org/10.1136/sextrans-2011-050298.
14. Corsaro D, Greub G. 2006. Pathogenic potential of novel chlamydiae and diagnostic approaches to infections due to these obligate intracellular bacteria. Clin. Microbiol. Rev. 19:283-297. http://dx.doi.org/10.1128 /CMR.19.2.283-297.2006.
15. Wang SP, Grayston JT. 1991. Three new serovars of Chlamydia trachomatis: Da, Ia, and L2a. J. Infect. Dis. 163:403-405. http://dx.doi.org/10.1093/infdis/163.2.403.
16. Baud D, Regan L, Greub G. 2008. Emerging role of Chlamydia and Chlamydia-like organisms in adverse pregnancy outcomes. Curr. Opin. Infect. Dis. 21:70-76. http://dx.doi.org/10.1097/QCO.0b013e3282f3e6a5.
17. Brunham RC, Rey-Ladino J. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149-161. http://dx.doi.org/10.1038/nri1551.
18. Wyrick PB. 2010. Chlamydia trachomatis persistence in vitro: an overview. J. Infect. Dis. 201(Suppl 2):S88-S95. http://dx.doi.org/10.1086 /652394.
19. Vergara MRC, Buendia Marin AJ, del Rio Alonzo L, Gijon FC, Hernandez NO, Ruiz MCG, Lorente JS. 2005. Chlamydia trachomatis genital infection: immunity and prospects for vaccine development. Immunologia 24:298-312.
20. Agrawal T, Bhengraj AR, Vats V, Salhan S, Mittal A. 2011. Expression of TLR 2, TLR 4 and iNOS in cervical monocytes of Chlamydia trachomatis-infected women and their role in host immune response. Am. J. Reprod. Immunol. 66:534-543. http://dx.doi.org/10.1111/j.1600-0897.2011.01064.x.
21. Refaat B, Al-Azemi M, Geary I, Eley A, Ledger W. 2009. Role of activins and inducible nitric oxide in the pathogenesis of ectopic pregnancy in patients with or without Chlamydia trachomatis infection. Clin. Vaccine Immunol. 16:1493-1503. http://dx.doi.org/10.1128/CVI.00221-09.
22. Rusconi B, Greub G. 2011. Chlamydiales and the innate immune response: friend or foe? FEMS Immunol. Med. Microbiol. 61:231-244. http://dx.doi.org/10.1111/j.1574-695X.2010.00772.x.
23. Register KB, Morgan PA, Wyrick PB. 1986. Interaction between Chlamydia spp. and human polymorphonuclear leukocytes in vitro. Infect. Immun. 52:664-670.
24. Yong EC, Klebanoff SJ, Kuo CC. 1982. Toxic effect of human polymorphonuclear leukocytes on Chlamydia trachomatis. Infect. Immun. 37: 422-426.
25. Barteneva N, Theodor I, Peterson EM, de la Maza LM. 1996. Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection. Infect. Immun. 64:4830-4833.
26. Kolaczkowska E, Kubes P. 2013. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13:159-175. http://dx.doi.org/10.1038/nri3399.
27. Salamone G, Giordano M, Trevani AS, Gamberale R, Vermeulen M, Schettinni J, Geffner JR. 2001. Promotion of neutrophil apoptosis by TNF-alpha. J. Immunol. 166:3476-3483.
28. van Zandbergen G, Gieffers J, Kothe H, Rupp J, Bollinger A, Aga E, Klinger M, Brade H, Dalhoff K, Maass M, Solbach W, Laskay T. 2004. Chlamydia pneumoniae multiply in neutrophil granulocytes and delay their spontaneous apoptosis. J. Immunol. 172:1768-1776.
29. Bradley LM, Douglass MF, Chatterjee D, Akira S, Baaten BJ. 2012. Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced Toll-like receptor signaling. PLoS Pathog. 8:e1002641. http://dx.doi.org/10.1371/journal.ppat.1002641.
30. Lee HY, Schripsema JH, Sigar IM, Murray CM, Lacy SR, Ramsey KH. 2010. A link between neutrophils and chronic disease manifestations of Chlamydia muridarum urogenital infection of mice. FEMS Immunol. Med. Microbiol. 59:108-116. http://dx.doi.org/10.1111/j.1574-695X.2010.00668.x.
31. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. 2013. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 10:230-252. http://dx.doi.org/10.1038/cmi.2013.10.
32. Shegarfi H, Sydnes K, Lovik M, Inngjerdingen M, Rolstad B, Naper C. 2009. The role of natural killer cells in resistance to the intracellular bacterium Listeria monocytogenes in rats. Scand. J. Immunol. 70:238-244. http://dx.doi.org/10.1111/j.1365-3083.2009.02292.x.
33. Tseng CT, Rank RG. 1998. Role of NK cells in early host response to chlamydial genital infection. Infect. Immun. 66:5867-5875.
34. Hook CE, Matyszak MK, Gaston JS. 2005. Infection of epithelial and dendritic cells by Chlamydia trachomatis results in IL-18 and IL-12 production, leading to interferon-gamma production by human natural killer cells. FEMS Immunol. Med. Microbiol. 45:113-120. http://dx.doi.org/10.1016/j.femsim.2005.02.010.
35. Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrne GI. 1994. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect. Immun. 62:3705-3711.
36. Jiao L, Gao X, Joyee AG, Zhao L, Qiu H, Yang M, Fan Y, Wang S, Yang X. 2011. NK cells promote type 1 T cell immunity through modulating the function of dendritic cells during intracellular bacterial infection. J. Immunol. 187:401-411. http://dx.doi.org/10.4049/jimmunol.1002519.
37. Zhao L, Gao X, Peng Y, Joyee AG, Bai H, Wang S, Yang J, Zhao W, Yang X. 2011. Differential modulating effect of natural killer (NK) T cells on interferon-gamma production and cytotoxic function of NK cells and its relationship with NK subsets in Chlamydia muridarum infection. Immunology 134:172-184. http://dx.doi.org/10.1111/j.1365-2567.2011.03477.x.
38. Godfrey DI, Stankovic S, Baxter AG. 2010. Raising the NKT cell family. Nat. Immunol. 11:197-206. http://dx.doi.org/10.1038/ni.1841.
39. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
40. Joyee AG, Qiu H, Fan Y, Wang S, Yang X. 2008. Natural killer T cells are critical for dendritic cells to induce immunity in chlamydial pneumonia. Am. J. Respir. Crit. Care Med. 178:745-756. http://dx.doi.org/10.1164/rccm.200804-517OC.
41. Tonti E, Galli G, Malzone C, Abrignani S, Casorati G, Dellabona P. 2009. NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood 113:370-376. http://dx.doi.org/10.1182/blood-2008-06-166249.
42. Joyee AG, Uzonna J, Yang X. 2010. Invariant NKT cells preferentially modulate the function of CD8 alpha_ dendritic cell subset in inducing type 1 immunity against infection. J. Immunol. 184:2095-2106. http://dx.doi.org/10.4049/jimmunol.0901348.
43. Bilenki L, Wang S, Yang J, Fan Y, Joyee AG, Yang X. 2005. NK T cell activation promotes Chlamydia trachomatis infection in vivo. J. Immunol. 175:3197-3206.
44. Wang H, Zhao L, Peng Y, Liu J, Qi M, Chen Q, Yang X, Zhao W. 2012. Protective role of alpha-galactosylceramide-stimulated natural killer T cells in genital tract infection with Chlamydia muridarum. FEMS Immunol. Med. Microbiol. 65:43-54. http://dx.doi.org/10.1111/j.1574-695X.2012.00939.x.
45. Morrison SG, Morrison RP. 2000. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect. Immun. 68:2870-2879. http://dx.doi.org/10.1128 /IAI.68.5.2870-2879.2000.
46. Beagley KW, Huston WM, Hansbro PM, Timms P. 2009. Chlamydial infection of immune cells: altered function and implications for disease. Crit. Rev. Immunol. 29:275-305. http://dx.doi.org/10.1615/CritRevIm munol.v29.i4.10.
47. Bas S, Neff L, Vuillet M, Spenato U, Seya T, Matsumoto M, Gabay C. 2008. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/ TLR1/TLR6 and CD14. J. Immunol. 180:1158-1168.
48. Yilma AN, Singh SR, Fairley SJ, Taha MA, Dennis VA. 2012. The anti-inflammatory cytokine, interleukin-10, inhibits inflammatory mediators in human epithelial cells and mouse macrophages exposed to live and UV-inactivated Chlamydia trachomatis. Mediators Inflamm. 2012: 520174. http://dx.doi.org/10.1155/2012/520174.
49. Sun HS, Eng EW, Jeganathan S, Sin AT, Patel PC, Gracey E, Inman RD, Terebiznik MR, Harrison RE. 2012. Chlamydia trachomatis vacuole maturation in infected macrophages. J. Leukoc. Biol. 92:815-827. http://dx.doi.org/10.1189/jlb.0711336.
50. Al-Zeer MA, Al-Younes HM, Lauster D, Abu Lubad M, Meyer TF. 2013. Autophagy restricts Chlamydia trachomatis growth in human macrophages via IFNG-inducible guanylate binding proteins. Autophagy 9:50-62. http://dx.doi.org/10.4161/auto.22482.
51. Yasir M, Pachikara ND, Bao X, Pan Z, Fan H. 2011. Regulation of chlamydial infection by host autophagy and vacuolar ATPase-bearing organelles. Infect. Immun. 79:4019-4028. http://dx.doi.org/10.1128/IAI.05308-11.
52. Crotzer VL, Blum JS. 2009. Autophagy and its role in MHC-mediated antigen presentation. J. Immunol. 182:3335-3341. http://dx.doi.org/10.4049/jimmunol.0803458.
53. Cao H, Wolff RG, Meltzer MS, Crawford RM. 1989. Differential regulation of class II MHC determinants on macrophages by IFNgamma and IL-4. J. Immunol. 143:3524-3531.
54. Vasilevsky S, Colino J, Puliaev R, Canaday DH, Snapper CM. 2008. Macrophages pulsed with Streptococcus pneumoniae elicit a T celldependent antibody response upon transfer into naive mice. J. Immunol. 181:1787-1797.
55. Jendro MC, Deutsch T, Korber B, Kohler L, Kuipers JG, Krausse-Opatz B, Westermann J, Raum E, Zeidler H. 2000. Infection of human monocyte-derived macrophages with Chlamydia trachomatis induces apoptosis of T cells: a potential mechanism for persistent infection. Infect. Immun. 68:6704-6711. http://dx.doi.org/10.1128/IAI.68.12.6704-6711.2000.
56. Jendro MC, Fingerle F, Deutsch T, Liese A, Kohler L, Kuipers JG, Raum E, Martin M, Zeidler H. 2004. Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor-alpha in vitro. Med. Microbiol. Immunol. 193:45-52. http://dx.doi.org/10.1007/s00430-003-0182-1.
57. Jiang X, Shen C, Rey-Ladino J, Yu H, Brunham RC. 2008. Characterization of murine dendritic cell line JAWS II and primary bone marrowderived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity. Infect. Immun. 76:2392-2401. http://dx.doi.org/10.1128/IAI.01584-07.
58. Matyszak MK, Young JL, Gaston JS. 2002. Uptake and processing of Chlamydia trachomatis by human dendritic cells. Eur. J. Immunol. 32: 742-751. http://dx.doi.org/10.1002/1521-4141(200203)32:3_742::AID-IMMU7423.0.CO;2-9.
59. Morrison RP, Feilzer K, Tumas DB. 1995. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect. Immun. 63:4661-4668.
60. Ojcius DM, Bravo de Alba Y, Kanellopoulos JM, Hawkins RA, Kelly KA, Rank RG, Dautry-Varsat A. 1998. Internalization of Chlamydia by dendritic cells and stimulation of Chlamydia-specific T cells. J. Immunol. 160:1297-1303.
61. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD. 1998. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J. Exp. Med. 188:809-818. http://dx.doi.org/10.1084/jem.188.5.809.
62. Lu H, Zhong G. 1999. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect. Immun. 67:1763-1769.
63. Shaw J, Grund V, Durling L, Crane D, Caldwell HD. 2002. Dendritic cells pulsed with a recombinant chlamydial major outer membrane protein antigen elicit a CD4(+) type 2 rather than type 1 immune response that is not protective. Infect. Immun. 70:1097-1105. http://dx.doi.org/10.1128/IAI.70.3.1097-1105.2002.
64. He Q, Moore TT, Eko FO, Lyn D, Ananaba GA, Martin A, Singh S, James L, Stiles J, Black CM, Igietseme JU. 2005. Molecular basis for the potency of IL-10-deficient dendritic cells as a highly efficient APC system for activating Th1 response. J. Immunol. 174:4860-4869.
65. Rey-Ladino J, Koochesfahani KM, Zaharik ML, Shen C, Brunham RC. 2005. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect. Immun. 73:1568-1577. http://dx.doi.org/10.1128/IAI.73.3.1568-1577.2005.
66. Yu H, Karunakaran KP, Kelly I, Shen C, Jiang X, Foster LJ, Brunham RC. 2011. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J. Immunol. 186:3615-3621. http://dx.doi.org/10.4049/jimmunol.1002952.
67. Ibana JA, Schust DJ, Sugimoto J, Nagamatsu T, Greene SJ, Quayle AJ. 2011. Chlamydia trachomatis immune evasion via downregulation of MHCclass I surface expression involves direct and indirect mechanisms. Infect. Dis. Obstet. Gynecol. 2011:420905. http://dx.doi.org/10.1155 /2011/420905.
68. Dong F, Pirbhai M, Zhong Y, Zhong G. 2004. Cleavage-dependent activation of a chlamydia-secreted protease. Mol. Microbiol. 52:1487-1494. http://dx.doi.org/10.1111/j.1365-2958.2004.04072.x.
69. Peschel G, Kernschmidt L, Cirl C, Wantia N, Ertl T, Durr S, Wagner H, Miethke T, Rodriguez N. 2010. Chlamydophila pneumoniae downregulates MHC-class II expression by two cell type-specific mechanisms. Mol. Microbiol. 76:648-661. http://dx.doi.org/10.1111/j.1365-2958.2010.07114.x.
70. Zhang XL, Tsui IS, Yip CM, Fung AW, Wong DK, Dai X, Yang Y, Hackett J, Morris C. 2000. Salmonella enterica serovar Typhi uses type IVB pili to enter human intestinal epithelial cells. Infect. Immun. 68: 3067-3073. http://dx.doi.org/10.1128/IAI.68.6.3067-3073.2000.
71. Zhong G, Fan P, Ji H, Dong F, Huang Y. 2001. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J. Exp. Med. 193:935-942. http://dx.doi.org /10.1084/jem.193.8.935.
72. Lu H, Wang H, Zhao HM, Zhao L, Chen Q, Qi M, Liu J, Yu H, Yu XP, Yang X, Zhao WM. 2010. Dendritic cells (DCs) transfected with a recombinant adenovirus carrying chlamydial major outer membrane protein antigen elicit protective immune responses against genital tract challenge infection. Biochem. Cell Biol. 88:757-765. http://dx.doi.org/10.1139/O10-011.
73. Li W, Murthy AK, Chaganty BK, Guentzel MN, Seshu J, Chambers JP, Zhong G, Arulanandam BP. 2011. Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital Chlamydia muridarum challenge. Front. Immunol. 2:73. http://dx.doi.org/10.3389/fimmu.2011.00073.
74. Rank RG, Soderberg LS, Barron AL. 1985. Chronic chlamydial genital infection in congenitally athymic nude mice. Infect. Immun. 48:847-849.
75. Johansson M, Lycke N. 2001. Immunological memory in B-celldeficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cells. Immunology 102:199-208. http://dx.doi.org/10.1046/j.1365-2567.2001.01167.x.
76. Kelly KA, Walker JC, Jameel SH, Gray HL, Rank RG. 2000. Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection. Infect. Immun. 68:1519-1528. http://dx.doi.org/10.1128/IAI.68.3.1519-1528.2000.
77. Olive AJ, Gondek DC, Starnbach MN. 2011. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol. 4:208-216. http://dx.doi.org/10.1038/mi.2010.58.
78. Van Voorhis WC, Barrett LK, Sweeney YT, Kuo CC, Patton DL. 1996. Analysis of lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper genital tract of female macaques infected with Chlamydia trachomatis. J. Infect. Dis. 174:647-650. http://dx.doi.org/10.1093/infdis/174.3.647.
79. Goodall JC, Beacock-Sharp H, Deane KH, Gaston JS. 2001. Recognition of the 60 kilodalton cysteine-rich outer membrane proteinOMP2by CD4(+) T cells from humans infected with Chlamydia trachomatis. Clin. Exp. Immunol. 126:488-493. http://dx.doi.org/10.1046/j.1365-2249.2001.01709.x.
80. Goodall JC, Yeo G, Huang M, Raggiaschi R, Gaston JS. 2001. Identification of Chlamydia trachomatis antigens recognized by human CD4+ T lymphocytes by screening an expression library. Eur. J. Immunol. 31: 1513-1522. http://dx.doi.org/10.1002/1521-4141(200105)31:5_1513::AID-IMMU15133.0.CO;2-U.
81. Holland MJ, Conway DJ, Blanchard TJ, Mahdi OM, Bailey RL, Whittle HC, Mabey DC. 1997. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin. Exp. Immunol. 107:44-49. http://dx.doi.org/10.1046/j.1365-2249.1997.2511129.x.
82. Kim SK, Devine L, Angevine M, DeMars R, Kavathas PB. 2000. Direct detection and magnetic isolation of Chlamydia trachomatis major outer membrane protein-specific CD8+ CTLs with HLA class I tetramers. J. Immunol. 165:7285-7292.
83. Ortiz L, Angevine M, Kim SK, Watkins D, DeMars R. 2000. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect. Immun. 68:1719-1723. http://dx.doi.org/10.1128/IAI.68.3.1719-1723.2000.
84. Deane KH, Jecock RM, Pearce JH, Gaston JS. 1997. Identification and characterization of a DR4-restricted T cell epitope within chlamydia heat shock protein 60. Clin. Exp. Immunol. 109:439-445. http://dx.doi.org /10.1046/j.1365-2249.1997.4711371.x.
85. Johnson RM, Yu H, Kerr MS, Slaven JE, Karunakaran KP, Brunham RC. 2012. PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice. Infect. Immun. 80:2204-2211. http://dx.doi.org/10.1128/IAI.06339-11.
86. Chen L, Lei L, Zhou Z, He J, Xu S, Lu C, Chen J, Yang Z, Wu G, Yeh IT, Zhong G, Wu Y. 2013. Contribution of interleukin-12 p35 (IL-12p35) and IL-12p40 to protective immunity and pathology in mice infected with Chlamydia muridarum. Infect. Immun. 81:2962-2971. http://dx.doi.org/10.1128/IAI.00161-13.
87. O'Connell CM, Ingalls RR, Andrews CW, Jr, Scurlock AM, Darville T. 2007. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J. Immunol. 179:4027-4034.
88. Olivares-Zavaleta N, Whitmire W, Gardner D, Caldwell HD. 2010. Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine 28:1454-1462. http://dx.doi.org/10.1016/j.vaccine.2009.11.073.
89. Vicetti Miguel RD, Harvey SA, LaFramboise WA, Reighard SD, Matthews DB, Cherpes TL. 2013. Human female genital tract infection by the obligate intracellular bacterium Chlamydia trachomatis elicits robust type 2 immunity. PLoS One 8:e58565. http://dx.doi.org/10.1371/journal.pone.0058565.
90. Farris CM, Morrison SG, Morrison RP. 2010. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccineinduced immunity to Chlamydia muridarum genital infection. Infect. Immun. 78:4374-4383. http://dx.doi.org/10.1128/IAI.00622-10.
91. Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E, Meoni E, Bonci A, Agnusdei M, Nardelli F, Bartolini E, Scarselli M, Caproni E, Laera D, Zedda L, Skibinski D, Giovinazzi S, Bastone R, Ianni E, Cevenini R, Grandi G, Grifantini R. 2011. Approach to discover T-and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc. Natl. Acad. Sci. U. S. A. 108:9969-9974. http://dx.doi.org/10.1073/pnas.1101756108.
92. Gondek DC, Olive AJ, Stary G, Starnbach MN. 2012. CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J. Immunol. 189:2441-2449. http://dx.doi.org/10.4049/jimmunol.1103032.
93. Jayarapu K, Kerr M, Ofner S, Johnson RM. 2010. Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and-independent mechanisms. J. Immunol. 185:6911-6920. http://dx.doi.org/10.4049/jimmunol.1002596.
94. Wizel B, Nystrom-Asklin J, Cortes C, Tvinnereim A. 2008. Role of CD8(+)T cells in the host response to Chlamydia. Microbes Infect. 10: 1420-1430. http://dx.doi.org/10.1016/j.micinf.2008.08.006.
95. Murthy AK, Li W, Chaganty BK, Kamalakaran S, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. 2011. Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection. Infect. Immun. 79:2928-2935. http://dx.doi.org/10.1128/IAI.05022-11.
96. Su H, Caldwell HD. 1995. CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect. Immun. 63:3302-3308.
97. Ibana JA, Myers L, Porretta C, Lewis M, Taylor SN, Martin DH, Quayle AJ. 2012. The major CD8 T cell effector memory subset in the normal and Chlamydia trachomatis-infected human endocervix is low in perforin. BMC Immunol. 13:66. http://dx.doi.org/10.1186/1471-2172-13-66.
98. Barenfanger J, MacDonald AB. 1974. The role of immunoglobulin in the neutralization of trachoma infectivity. J. Immunol. 113:1607-1617.
99. Jawetz E, Rose L, Hanna L, Thygeson P. 1965. Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA 194:620-632.
100. Bartolini E, Ianni E, Frigimelica E, Petracca R, Galli G, Scorza FB, Norais N, Laera D, Giusti F, Pierleoni A, Donati M, Cevenini R, Finco O, Grandi G, Grifantini R. 2013. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro. J. Extracell. Vesicles 2013:2. http://dx.doi.org/10.3402/jev.v2i0.20181.
101. Byrne GI, Stephens RS, Ada G, Caldwell HD, Su H, Morrison RP, Van der Pol B, Bavoil P, Bobo L, Everson S, Ho Y, Hsia RC, Kenendy K, Kuo C-C, Montgomery PC, Peterson E, Swanson A, Whitaker C, Whittum Hudson J, Yang CL, Zhang Y-X, Zhong GM. 1993. Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. J. Infect. Dis. 168:415-420. http://dx.doi.org/10.1093 /infdis/168.2.415.
102. Morrison SG, Morrison RP. 2005. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175:7536-7542.
103. Murthy AK, Chaganty BK, Li W, Guentzel MN, Chambers JP, Seshu J, Zhong G, Arulanandam BP. 2009. A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge. FEMS Immunol. Med. Microbiol. 55:271-279. http://dx.doi.org/10.1111/j.1574-695X.2008.00517.x.
104. Moore T, Ananaba GA, Bolier J, Bowers S, Belay T, Eko FO, Igietseme JU. 2002. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 105:213-221. http://dx.doi.org/10.1046/j.0019-2805.2001.01354.x.
105. Igietseme JU, Eko FO, He Q, Black CM. 2004. Antibody regulation of T cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev. Vaccines 3:23-34. http://dx.doi.org/10.1586 /14760584.3.1.23.
106. Verweij SP, Bax CJ, Quint KD, Quint WG, van Leeuwen AP, Peters RP, Oostvogel PM, Mutsaers JA, Dorr PJ, Pleijster J, Ouburg S, Morre SA. 2009. Significantly higher serologic responses of Chlamydia trachomatis B group serovars versus C and I serogroups. Drugs Today (Barc.) 45(Suppl B):135-140.
107. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. 1999. Chlamydia infections and heart disease linked through antigenic mimicry. Science 283:1335-1339. http://dx.doi.org/10.1126/science.283.5406.1335.
108. Domeika M, Domeika K, Paavonen J, Mardh PA, Witkin SS. 1998. Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic in-flammatory disease. J. Infect. Dis. 177:714-719. http://dx.doi.org/10.1086/514218.
109. Witkin SS. 2002. Immunological aspects of genital chlamydia infections. Best Pract. Res. Clin. Obstet. Gynaecol. 16:865-874. http://dx.doi.org/10.1053/beog.2002.0326.
110. Hjelholt A, Christiansan G, Johansson TG, Ingerslev HJ, Birkelund S. 2011. Tubal factor infertility is associated with antibodies against Chlamydia trachomatis heat shock protein 60 (HSP60) but not human HSP60. Human Reprod. 26:2069-2076. http://dx.doi.org/10.1093 /humrep/der167.
111. Fernandez-Boyanapalli R, McPhillips KA, Frasch SC, Janssen WJ, Dinauer MC, Riches DW, Henson PM, Byrne A, Bratton DL. 2010. Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-gamma in a nitric oxidedependent manner. J. Immunol. 185:4030-4041. http://dx.doi.org/10.4049/jimmunol.1001778.
112. Zhong GM, de la Maza LM. 1988. Activation of mouse peritoneal macrophages in vitro or in vivo by recombinant murine gamma interferon inhibits the growth of Chlamydia trachomatis serovar L1. Infect. Immun. 56:3322-3325.
113. Al-Younes HM, Rudel T, Brinkmann V, Szczepek AJ, Meyer TF. 2001. Low iron availability modulates the course of Chlamydia pneumoniae infection. Cell. Microbiol. 3:427-437. http://dx.doi.org/10.1046/j.1462-5822.2001.00125.x.
114. Ryu SY, Jeong KS, Kang BN, Park SJ, Yoon WK, Kim SH, Kim TH. 2000. Modulation of transferrin synthesis, transferrin receptor expression, iNOS expression and NO production in mouse macrophages by cytokines, either alone or in combination. Anticancer Res. 20:3331-3338.
115. Nairz M, Fritsche G, Brunner P, Talasz H, Hantke K, Weiss G. 2008. Interferon-gamma limits the availability of iron for intramacrophage Salmonella typhimurium. Eur. J. Immunol. 38:1923-1936. http://dx.doi.org/10.1002/eji.200738056.
116. Akers JC, Tan M. 2006. Molecular mechanism of tryptophandependent transcriptional regulation in Chlamydia trachomatis. J. Bacteriol. 188:4236-4243. http://dx.doi.org/10.1128/JB.01660-05.
117. Zhang Y, Wang H, Ren J, Tang X, Jing Y, Xing D, Zhao G, Yao Z, Yang X, Bai H. 2012. IL-17A synergizes with IFN-gamma to upregulate iNOS and NO production and inhibit chlamydial growth. PLoS One 7:e39214. http://dx.doi.org/10.1371/journal.pone.0039214.
118. De Clercq E, Kalmar I, Vanrompay D. 2013. Animal models for studying female genital tract infection with Chlamydia trachomatis. Infect. Immun. 81:3060-3067. http://dx.doi.org/10.1128/IAI.00357-13.
119. Riley MM, Zurenski MA, Frazer LC, O'Connell CM, Andrews CW, Jr, Mintus M, Darville T. 2012. The recall response induced by genital challenge with Chlamydia muridarum protects the oviduct from pathology but not from reinfection. Infect. Immun. 80:2194-2203. http://dx.doi.org/10.1128/IAI.00169-12.
120. Shah AA, Schripsema JH, Imtiaz MT, Sigar IM, Kasimos J, Matos PG, Inouye S, Ramsey KH. 2005. Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex. Transm. Dis. 32:49-56. http://dx.doi.org/10.1097/01.olq.0000148299.14513.11.
121. Tang L, Zhang H, Lei L, Gong S, Zhou Z, Baseman J, Zhong G. 2013. Oviduct infection and hydrosalpinx in DBA1/j mice is induced by intracervical but not intravaginal inoculation with Chlamydia muridarum. PLoS One 8:e71649. http://dx.doi.org/10.1371/journal.pone.0071649.
122. Farris CM, Morrison RP. 2011. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect. Immun. 79: 986-996. http://dx.doi.org/10.1128/IAI.00881-10.
123. Rank RG, Whittum-Hudson JA. 2010. Protective immunity to chlamydial genital infection: evidence from animal studies. J. Infect. Dis. 201(Suppl 2):S168-S177. http://dx.doi.org/10.1086/652399.
124. Carmichael JR, Pal S, Tifrea D, de la Maza LM. 2011. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine 29:5276-5283. http://dx.doi.org/10.1016/j.vaccine.2011.05.013.
125. Lyons JM, Ito JI, Jr, Pena AS, Morre SA. 2005. Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum. J. Clin. Pathol. 58:397-401. http://dx.doi.org/10.1136/jcp.2004.021543.
126. Ripa KT, Moller BR, Mardh PA, Freundt EA, Melsen F. 1979. Experimental acute salpingitis in grivet monkeys provoked by Chlamydia trachomatis. Acta Pathol. Microbiol. Scand. B 87B:65-70.
127. Johnson AP, Hetherington CM, Osborn MF, Thomas BJ, Taylor-Robinson D. 1980. Experimental infection of the marmoset genital tract with Chlamydia trachomatis. Br. J. Exp. Pathol. 61:291-295.
128. Bell JD, Bergin IL, Harris LH, Chai D, Mullei I, Mwenda J, Dalton VK, Vahratian A, Lebar W, Zochowski MK, Kiulia N, Aronoff DM, Patton DL. 2011. The effects of a single cervical inoculation of Chlamydia trachomatis on the female reproductive tract of the baboon (Papio anubis). J. Infect. Dis. 204:1305-1312. http://dx.doi.org/10.1093/infdis/jir541.
129. Patton DL, Sweeney YT, Paul KJ. 2009. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex. Transm. Dis. 36:350-356. http://dx.doi.org/10.1097/OLQ.0b013e318195c31a.
130. Patton DL, Kuo CC, Wang SP, Halbert SA. 1987. Distal tubal obstruction induced by repeated Chlamydia trachomatis salpingeal infections in pig-tailed macaques. J. Infect. Dis. 155:1292-1299. http://dx.doi.org/10.1093/infdis/155.6.1292.
131. Cunningham KA, Beagley KW. 2008. Male genital tract chlamydial infection: implications for pathology and infertility. Biol. Reprod. 79: 180-189. http://dx.doi.org/10.1095/biolreprod.108.067835.
132. Miyairi I, Ramsey KH, Patton DL. 2010. Duration of untreated chlamydial genital infection and factors associated with clearance: review of animal studies. J. Infect. Dis. 201(Suppl 2):S96-S103. http://dx.doi.org /10.1086/652393.
133. Rank RG, Sanders MM, Kidd AT. 1993. Influence of the estrous cycle on the development of upper genital tract pathology as a result of chlamydial infection in the guinea pig model of pelvic inflammatory disease. Am. J. Pathol. 142:1291-1296.
134. Ficarra M, Ibana JS, Poretta C, Ma L, Myers L, Taylor SN, Greene S, Smith B, Hagensee M, Martin DH, Quayle AJ. 2008. A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection. Am. J. Reprod. Immunol. 60:415-425. http://dx.doi.org/10.1111/j.1600-0897.2008.00639.x.
135. Rank RG, Bowlin AK, Kelly KA. 2000. Characterization of lymphocyte response in the female genital tract during ascending chlamydial genital infection in the guinea pig model. Infect. Immun. 68:5293-5298. http: //dx.doi.org/10.1128/IAI.68.9.5293-5298.2000.
136. Tuggle CK, Green JA, Fitzsimmons C, Woods R, Prather RS, Malchenko S, Soares BM, Kucaba T, Crouch K, Smith C, Tack D, Robinson N, O'Leary B, Scheetz T, Casavant T, Pomp D, Edeal BJ, Zhang Y, Rothschild MF, Garwood K, Beavis W. 2003. EST-based gene discovery in pig: virtual expression patterns and comparative mapping to human. Mamm. Genome 14:565-579. http://dx.doi.org/10.1007/s00335-002-2263-7.
137. Vanrompay D, Hoang TQ, De Vos L, Verminnen K, Harkinezhad T, Chiers K, Morre SA, Cox E. 2005. Specific-pathogen-free pigs as an animal model for studying Chlamydia trachomatis genital infection. Infect. Immun. 73:8317-8321. http://dx.doi.org/10.1128/IAI.73.12.8317-8321.2005.
138. Schautteet K, De Clercq E, Jonsson Y, Lagae S, Chiers K, Cox E, Vanrompay D. 2012. Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization. Vaccine 30:2869-2881. http://dx.doi.org/10.1016/j.vaccine.2012.02.044.
139. Schautteet K, Stuyven E, Beeckman DS, Van Acker S, Carlon M, Chiers K, Cox E, Vanrompay D. 2011. Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa. Vaccine 29:1399-1407. http://dx.doi.org /10.1016/j.vaccine.2010.12.042.
140. Schautteet K, Stuyven E, Cox E, Vanrompay D. 2011. Validation of the Chlamydia trachomatis genital challenge pig model for testing recombinant protein vaccines. J. Med. Microbiol. 60:117-127. http://dx.doi.org /10.1099/jmm.0.024448-0.
141. Wolner-Hanssen P, Patton DL, Holmes KK. 1991. Protective immunity in pig-tailed macaques after cervical infection with Chlamydia trachomatis. Sex. Transm. Dis. 18:21-25. http://dx.doi.org/10.1097/00007435-199101000-00005.
142. Geisler WM. 2010. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J. Infect. Dis. 201(Suppl 2):S104-S113. http://dx.doi.org/10.1086/652402.
143. Molano M, Meijer CJ, Weiderpass E, Arslan A, Posso H, Franceschi S, Ronderos M, Munoz N, van den Brule AJ. 2005. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J. Infect. Dis. 191:907-916. http://dx.doi.org/10.1086/428287.
144. Batteiger BE, Xu F, Johnson RE, Rekart ML. 2010. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J. Infect. Dis. 201(Suppl 2):S178-S189. http://dx.doi.org/10.1086 /652400.
145. Huston WM, Harvie M, Mittal A, Timms P, Beagley KW. 2012. Vaccination to protect against infection of the female reproductive tract. Expert Rev. Clin. Immunol. 8:81-94. http://dx.doi.org/10.1586 /eci.11.80.
146. Entrican G, Wheelhouse N, Wattegedera SR, Longbottom D. 2012. New challenges for vaccination to prevent chlamydial abortion in sheep. Comp. Immunol. Microbiol. Infect. Dis. 35:271-276. http://dx.doi.org /10.1016/j.cimid.2011.12.001.
147. Igietseme JU, Black CM. 2013. Chlamydial infection: a clinical and public health perspective. S. Karger AG, Basel, Switzerland.
148. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. 2007. Current status of veterinary vaccines. Clin. Microbiol. Rev. 20:489-510. http://dx.doi.org/10.1128/CMR.00005-07.
149. Grayston JT, Wang SP. 1978. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex. Transm. Dis. 5:73-77. http://dx.doi.org/10.1097/00007435-197804000-00011.
150. Brunham RC. 2013. Immunity to Chlamydia trachomatis. J. Infect. Dis. 207:1796-1797. http://dx.doi.org/10.1093/infdis/jit095.
151. Schautteet K, De Clercq E, Vanrompay D. 2011. Chlamydia trachomatis vaccine research through the years. Infect. Dis. Obstet. Gynecol. 2011: 963513. http://dx.doi.org/10.1155/2011/963513.
152. Grayston JT, Woolridge RL, Wang SP, Yen CH, Yang CY, Cheng KH, Chang IH. 1963. Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. Proc. Soc. Exp. Biol. Med. 112:589-595. http://dx.doi.org/10.3181 /00379727-112-28112.
153. Sowa S, Sowa J, Collier LH, Blyth WA. 1969. Trachoma vaccine field trials in The Gambia. J. Hyg. (Lond.) 67:699-717. http://dx.doi.org/10.1017/S0022172400042157.
154. Detmer A, Glenting J. 2006. Live bacterial vaccines-a review and identification of potential hazards. Microb. Cell Fact. 5:23. http://dx.doi.org /10.1186/1475-2859-5-23.
155. Nunes A, Nogueira PJ, Borrego MJ, Gomes JP. 2010. Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B-and T-cell epitopes: worldwide survey. PLoS One 5:e13171. http://dx.doi.org/10.1371/journal.pone.0013171.
156. Pal S, Theodor I, Peterson EM, de la Maza LM. 1997. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun. 65:3361-3369.
157. Pal S, Theodor I, Peterson EM, de la Maza LM. 2001. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69:6240-6247. http://dx.doi.org/10.1128/IAI.69.10.6240-6247.2001.
158. Tifrea DF, Sun G, Pal S, Zardeneta G, Cocco MJ, Popot JL, de la Maza LM. 2011. Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine. Vaccine 29:4623-4631. http://dx.doi.org/10.1016/j.vaccine.2011.04.065.
159. Igietseme JU, Murdin A. 2000. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune responsestimulating complexes. Infect. Immun. 68:6798-6806. http://dx.doi.org /10.1128/IAI.68.12.6798-6806.2000.
160. Cheng C, Bettahi I, Cruz-Fisher MI, Pal S, Jain P, Jia Z, Holmgren J, Harandi AM, de la Maza LM. 2009. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine 27:6239-6246. http: //dx.doi.org/10.1016/j.vaccine.2009.07.108.
161. Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. 2011. Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. Vaccine 29:3456-3464. http://dx.doi.org/10.1016/j.vaccine.2011.02.057.
162. Cruz-Fisher MI, Cheng C, Sun G, Pal S, Teng A, Molina DM, Kayala MA, Vigil A, Baldi P, Felgner PL, Liang X, de la Maza LM. 2011. Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice. Infect. Immun. 79:246-257. http://dx.doi.org/10.1128/IAI.00626-10.
163. Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G. 2010. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J. Immunol. 185:1670-1680. http://dx.doi.org/10.4049/jimmunol.1001240.
164. Longbottom D. 2003. Chlamydial vaccine development. J. Med. Microbiol. 52:537-540. http://dx.doi.org/10.1099/jmm.0.05093-0.
165. Zhu S, Chen J, Zheng M, Gong W, Xue X, Li W, Zhang L. 2010. Identification of immunodominant linear B-cell epitopes within the major outer membrane protein of Chlamydia trachomatis. Acta Biochim. Biophys. Sin. (Shanghai) 42:771-778. http://dx.doi.org/10.1093/abbs /gmq087.
166. Sun G, Pal S, Weiland J, Peterson EM, de la Maza LM. 2009. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27:5020-5025. http://dx.doi.org/10.1016/j.vaccine.2009.05.008.
167. O'Meara CP, Armitage CW, Harvie MC, Timms P, Lycke NY, Beagley KW. 2013. Immunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathology. PLoS One 8:e61962. http://dx.doi.org /10.1371/journal.pone.0061962.
168. Tifrea DF, Ralli-Jain P, Pal S, de la Maza LM. 2013. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect. Immun. 81:1741-1750. http://dx.doi.org/10.1128/IAI.00734-12.
169. Kalbina I, Wallin A, Lindh I, Engstrom P, Andersson S, Strid K. 2011. A novel chimeric MOMP antigen expressed in Escherichia coli, Arabidopsis thaliana, and Daucus carota as a potential Chlamydia trachomatis vaccine candidate. Protein Expr. Purif. 80:194-202. http://dx.doi.org/10.1016/j.pep.2011.08.010.
170. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. 2007. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect. Immun. 75:666-676. http://dx.doi.org/10.1128/IAI.01280-06.
171. Murthy AK, Li W, Guentzel MN, Zhong G, Arulanandam BP. 2011. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine 29:2519-2522. http://dx.doi.org/10.1016 /j.vaccine.2011.01.074.
172. Li Z, Lu C, Peng B, Zeng H, Zhou Z, Wu Y, Zhong G. 2012. Induction of protective immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen phosphorylase. PLoS One 7:e32997. http://dx.doi.org/10.1371/journal.pone.0032997.
173. Olsen AW, Theisen M, Christensen D, Follmann F, Andersen P. 2010. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 5:e10768. http://dx.doi.org/10.1371/journal.pone.0010768.
174. Lu C, Peng B, Li Z, Lei L, Li Z, Chen L, He Q, Zhong G, Wu Y. 2013. Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator. Microbes Infect. 15:329-338. http://dx.doi.org/10.1016/j.micinf.2013.02.001.
175. Longbottom D, Livingstone M. 2006. Vaccination against chlamydial infections of man and animals. Vet. J. 171:263-275. http://dx.doi.org/10.1016/j.tvjl.2004.09.006.
176. Kumar U, Kumar S, Varghese S, Chamoli R, Barthwal P. 2013. DNA vaccine: a modern biotechnological approach towards human welfare and clinical trials. Int. J. Res. Biomed. Biotechnol. 3:17-20.
177. Pal S, Barnhart KM, Wei Q, Abai AM, Peterson EM, de la Maza LM. 1999. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17:459-465. http: //dx.doi.org/10.1016/S0264-410X(98)00219-9.
178. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC. 2000. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect. Immun. 68:3074-3078. http://dx.doi.org/10.1128/IAI.68.6.3074-3078.2000.
179. Ou C, Tian D, Ling Y, Pan Q, He Q, Eko FO, He C. 2013. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets. Int. Immunopharmacol. 16:505-510. http://dx.doi.org/10.1016/j.intimp.2013.04.027.
180. Xu W, Liu J, Gong W, Chen J, Zhu S, Zhang L. 2011. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1. Vaccine 29:2672-2678. http://dx.doi.org/10.1016/j.vaccine.2010.12.132.
181. Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. 2010. The bacterial ghost platform system: production and applications. Bioeng. Bugs 1:326-336. http://dx.doi.org/10.4161/bbug.1.5.12540.
182. Ifere GO, He Q, Igietseme JU, Ananaba GA, Lyn D, Lubitz W, Kellar KL, Black CM, Eko FO. 2007. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J. Microbiol. Immunol. Infect. 40:188-200.
183. Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. 2011. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine 29:3802-3810. http://dx.doi.org/10.1016/j.vaccine.2011.03.027.
184. Luzardo-Alvarez A, Blarer N, Peter K, Romero JF, Reymond C, Corradin G, Gander B. 2005. Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J. Control Release 109:62-76. http://dx.doi.org/10.1016/j.jconrel.2005.09.015.
185. Waeckerle-Men Y, Groettrup M. 2005. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv. Drug Deliv. Rev. 57:475-482. http://dx.doi.org/10.1016/j.addr.2004.09.007.
186. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. 2008. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26:5046-5057. http://dx.doi.org/10.1016/j.vaccine.2008.07.035.
187. Waeckerle-Men Y, Gander B, Groettrup M. 2005. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol. Med. 109:35-46.
188. Boyoglu S, Vig K, Pillai S, Rangari V, Dennis VA, Khazi F, Singh SR. 2009. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine 5:463-472. http://dx.doi.org/10.1016/j.nano.2009.02.004.
189. Fairley SJ, Singh SR, Yilma AN, Waffo AB, Subbarayan P, Dixit S, Taha MA, Cambridge CD, Dennis VA. 2013. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine. Int. J. Nanomedicine 8:2085-2099. http://dx.doi.org/10.2147/IJN.S44155.
190. Taha MA, Singh SR, Dennis VA. 2012. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide. Nanotechnology 23:325101. http://dx.doi.org /10.1088/0957-4484/23/32/325101.
191. Cambridge CD, Singh SR, Waffo AB, Fairley SJ, Dennis VA. 2013. Formulation, characterization, and expression of a recombinantMOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int. J. Nanomedicine 8:1759-1771. http://dx.doi.org/10.2147/IJN.S42723.
192. Childs TS, Webley WC. 2012. In vitro assessment of halobacterial gas vesicles as a Chlamydia vaccine display and delivery system. Vaccine 30:5942-5948. http://dx.doi.org/10.1016/j.vaccine.2012.07.038.
193. Sremac M, Stuart ES. 2008. Recombinant gas vesicles from Halobacterium sp. displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle. BMC Biotechnol. 8:9. http://dx.doi.org/10.1186/1472-6750-8-9.
194. Sremac M, Stuart ES. 2010. SIVsm Tat, Rev, and Nef1: functional characteristics of r-GV internalization on isotypes, cytokines, and intracellular degradation. BMC Biotechnol. 10:54. http://dx.doi.org/10.1186/1472-6750-10-54.
195. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. 2010. New adjuvants for human vaccines. Curr. Opin. Immunol. 22:411-416. http: //dx.doi.org/10.1016/j.coi.2010.04.004.
196. O'Hagan DT. 2007. New generation vaccine adjuvants, p 1-7. In Encyclopedia of life sciences. John Wiley and Sons, Hoboken, NJ. http://dx.doi.org/10.1002/9780470015902.a0020177.
197. O'Hagan DT, Rappuoli R. 2004. Novel approaches to vaccine delivery. Pharm. Res. 21:1519-1530. http://dx.doi.org/10.1023/B:PHAM.0000041443.17935.33.
198. Sokolovska A, Hem SL, HogenEsch H. 2007. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminumcontaining adjuvants. Vaccine 25:4575-4585. http://dx.doi.org/10.1016 /j.vaccine.2007.03.045.
199. Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham RC. 2012. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect. Immun. 80:1510-1518. http://dx.doi.org/10.1128/IAI.06338-11.
200. Nolz JC, Starbeck-Miller GR, Harty JT. 2011. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy 3:1223-1233. http://dx.doi.org/10.2217/imt.11.100.
201. Perry LL, Feilzer K, Portis JL, Caldwell HD. 1998. Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice. J. Immunol. 160:2905-2914.
202. Kelly KA, Chan AM, Butch A, Darville T. 2009. Two different homing pathways involving integrin beta7 and E-selectin significantly influence trafficking of CD4 cells to the genital tract following Chlamydia muridarum infection. Am. J. Reprod. Immunol. 61:438-445. http://dx.doi.org/10.1111/j.1600-0897.2009.00704.x.
203. Brandtzaeg P. 2009. Mucosal immunity: induction, dissemination, and effector functions. Scand. J. Immunol. 70:505-515. http://dx.doi.org/10.1111/j.1365-3083.2009.02319.x.
204. Naz RK. 2012. Female genital tract immunity: distinct immunological challenges for vaccine development. J. Reprod. Immunol. 93:1-8. http: //dx.doi.org/10.1016/j.jri.2011.09.005.
205. Gallichan WS, Rosenthal KL. 1998. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1155-1161. http://dx.doi.org/10.1086/515286.
206. Gupta S, Janani R, Bin Q, Luciw P, Greer C, Perri S, Legg H, Donnelly J, Barnett S, O'Hagan D, Polo JM, Vajdy M. 2005. Characterization of human immunodeficiency virus Gag-specific gamma interferonexpressing cells following protective mucosal immunization with alphavirus replicon particles. J. Virol. 79:7135-7145. http://dx.doi.org/10.1128/JVI.79.11.7135-7145.2005.
207. Jiang JQ, Patrick A, Moss RB, Rosenthal KL. 2005. CD8+ T-cellmediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol. 79:393-400. http://dx.doi.org /10.1128/JVI.79.1.393-400.2005.
208. Lindqvist M, Persson J, Thorn K, Harandi AM. 2009. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182:6435-6443. http://dx.doi.org/10.4049/jimmunol.0900136.
209. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, BenMohamed L. 2009. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemicCD8+T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2:129-143. http://dx.doi.org/10.1038 /mi.2008.81.
210. Hickey DK, Aldwell FE, Beagley KW. 2010. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection. Vaccine 28:1668-1672. http://dx.doi.org/10.1016/j.vaccine.2009.12.010.
211. He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Bandea C, Ananaba GA, Black CM, Igietseme JU. 2007. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology 122:28-37. http://dx.doi.org/10.1111/j.1365-2567.2007.02608.x.
212. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. 2003. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21:1455-1465. http://dx.doi.org/10.1016/S0264-410X(02)00680-1.
213. Eko FO, Ekong E, He Q, Black CM, Igietseme JU. 2011. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine 29: 1472-1480. http://dx.doi.org/10.1016/j.vaccine.2010.12.024.
214. Ralli-Jain P, Tifrea D, Cheng C, Pal S, de la Maza LM. 2010. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 28:7659-7666. http://dx.doi.org/10.1016/j.vaccine.2010.09.040.
215. Cunningham KA, Carey AJ, Hafner L, Timms P, Beagley KW. 2011. Chlamydia muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo. Am. J. Reprod. Immunol. 65:118-126. http://dx.doi.org/10.1111/j.1600-0897.2010.00894.x.
216. Goosen N, Moolenaar GF. 2008. Repair of UV damage in bacteria. DNA Repair (Amst.) 7:353-379. http://dx.doi.org/10.1016/j.dnarep.2007.09.002.
217. Ding Y, Liu R, Rong J, Xiong S. 2014. Heat-induced denaturation and aggregation of actomyosin and myosin from yellowcheek carp during setting. Food Chem. 149:237-243. http://dx.doi.org/10.1016/j.foodchem.2013.10.123.
218. Rank RG, Batteiger BE, Soderberg LS. 1990. Immunization against chlamydial genital infection in guinea pigs with UV-inactivated and viable chlamydiae administered by different routes. Infect. Immun. 58: 2599-2605.
219. Brunham RC, Pourbohloul B, Mak S, White R, Rekart ML. 2005. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J. Infect. Dis. 192:1836-1844. http: //dx.doi.org/10.1086/497341.
220. Atik B, Thanh TT, Luong VQ, Lagree S, Dean D. 2006. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 296:1488-1497. http://dx.doi.org/10.1001/jama.296.12.1488.
221. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, Cevallos V, Zhou Z, Maxey K, Lee DC, Shapiro BL, Srinivasan M, Porco T, Whitcher JP, Gaynor BD, Lietman TM. 2006. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 295:1142-1146. http://dx.doi.org/10.1001/jama.295.10.1142.
222. Lal JA, Malogajski J, Verweij SP, de Boer P, Ambrosino E, Brand A, Ouburg S, Morre SA. 2013. Chlamydia trachomatis infections and subfertility: opportunities to translate host pathogen genomic data into public health. Public Health Genomics 16:50-61. http://dx.doi.org/10.1159 /000346207.
223. Morré SA, Karimi O, Ouburg S. 2009. Chlamydia trachomatis: identification of susceptibility markers for ocular and sexually transmitted infection by immunogenetics. FEMS Immunol. Med. Microbiol. 55:140-153. http://dx.doi.org/10.1111/j.1574-695X.2009.00536.x.
224. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J. 2011. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med. 8:e1001147. http://dx.doi.org/10.1371/journal.pmed.1001147.
225. Jit M, Choi YH, Edmunds WJ. 2008. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337:a769. http: //dx.doi.org/10.1136/bmj.a769.
226. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. 2011. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J. Infect. Dis. 204:372-376. http://dx.doi.org/10.1093/infdis/jir285.
227. FDA. Accessed 19 October 2009. Gardasil approval letter. FDA, Rockville, MD. http://www.fda.gov/BiologicsBloodVaccines/Vaccines /ApprovedProducts/ucm186991.htm.
228. Quinn TC, Gaydos C, Shepherd M, Bobo L, Hook EW, 3rd, Viscidi R, Rompalo A. 1996. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 276:1737-1742.
229. Gray RT, Beagley KW, Timms P, Wilson DP. 2009. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J. Infect. Dis. 199:1680-1688. http://dx.doi.org/10.1086/598983.
230. Dang T, Jaton-Ogay K, Flepp M, Kovari H, Evison JM, Fehr J, Schmid P, Boffi El Amari E, Cavassini M, Odorico M, Tarr PE, Greub G. 2009. High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. Clin. Infect. Dis. 49:1532-1535. http://dx.doi.org/10.1086/644740.
231. Malhotra M, Sood S, Mukherjee A, Muralidhar S, Bala M. 2013. Genital Chlamydia trachomatis: an update. Indian J. Med. Res. 138:303-316.
232. Lacy HM, Bowlin AK, Hennings L, Scurlock AM, Nagarajan UM, Rank RG. 2011. Essential role for neutrophils in pathogenesis and adaptive immunity in Chlamydia caviae ocular infections. Infect. Immun. 79:1889-1897. http://dx.doi.org/10.1128/IAI.01257-10.
233. Gall A, Horowitz A, Joof H, Natividad A, Tetteh K, Riley E, Bailey RL, Mabey DC, Holland MJ. 2011. Systemic effector and regulatory immune responses to chlamydial antigens in trachomatous trichiasis. Front. Microbiol. 2:10. http://dx.doi.org/10.3389/fmicb.2011.00010.
234. Picard MD, Cohane KP, Gierahn TM, Higgins DE, Flechtner JB. 2012. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 30:4387-4393. http://dx.doi.org/10.1016/j.vaccine.2012.01.017.
235. Cheng C, Cruz-Fisher MI, Tifrea D, Pal S, Wizel B, de la Maza LM. 2011. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31(R). Vaccine 29:2437-2443. http://dx.doi.org/10.1016/j.vaccine.2011.01.031.
236. Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S, Bonci A, Petracca R, Bartolini E, Galli G, Agnusdei M, Nardelli F, Buricchi F, Norais N, Ferlenghi I, Donati M, Cevenini R, Finco O, Grandi G, Grifantini R. 2009. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. Infect. Immun. 77:4168-4176. http://dx.doi.org/10.1128 /IAI.00344-09.
237. Clifton DR, Fields KA, Grieshaber SS, Dooley CA, Fischer ER, Mead DJ, Carabeo RA, Hackstadt T. 2004. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc. Natl. Acad. Sci. U. S. A. 101:10166-10171. http://dx.doi.org/10.1073/pnas.0402829101.